This federal contract award, valued at $134,862.00, was issued by the Department of Veterans Affairs (VA) to Trillamed LLC, a service-disabled veteran-owned small business, for the delivery of specialized radiopharmaceuticals known as Axumin, Amyvid, and Cerianna. These diagnostic medications are used for detecting prostate cancer, breast cancer, and Alzheimer's disease, respectively. The contract has an ultimate completion date of December 31, 2024.
The original procurement was sole-sourced to Trillamed and PetNet Solutions, a Siemens company, as the authorized distributors of these proprietary radiopharmaceuticals. This sole-source approach was taken under the authority of FAR 6.302-1(a)(2), which allows for single-source procurement when only one responsible source can satisfy the agency's requirements. The VA's nuclear medicine service sought to acquire these state-of-the-art radiopharmaceuticals for diagnostic patient care at the Louis Stokes Cleveland VA Medical Center.
Generated 11/28/24, 9:39 AM